WINNIPEG, MB--(Marketwired - January 06, 2017) - 3D Signatures Inc. (TSX VENTURE: DXD) (OTCQB: TDSGF) (FRANKFURT: 3D0) (the "Company" or "3DS") is pleased to announce the appointment of Joost van der Mark as its Chief Business Officer ("CBO"), effective January 6, 2017, subject to approval of the TSXV. Mr. van der Mark brings more than two decades of executive experience to 3DS, having worked with several major international healthcare companies as well as earlier stage biotechnology and healthcare firms.

Mr. van der Mark has an accomplished history of strategic operations, sales and marketing, clinical research, market access, business development and general management success in the global healthcare industry. He joins 3DS from BioSyent Inc., where he served as Vice President of Corporate Development with responsibility for business development and market access initiatives. Prior to joining BioSyent, Mr. van der Mark co-founded Orphan Canada, which subsequently sold its assets to Knight Therapeutics in 2014. In a career spanning more than two decades, he has also held progressive positions at Bayer, Sanofi and Nycomed. Mr. van der Mark has a M.Sc. in Physiology/Pharmacology from Western University and a MBA from York University (Schulich).

"We are very pleased to have recruited an executive of Joost's caliber to this key position with the Company," said 3DS' CEO, Jason Flowerday. "Joost is a seasoned leader with a strong track record of delivering strategic guidance and profitable growth to both major international pharmaceutical companies and emerging healthcare companies. I have tremendous confidence in his ability to help us establish valuable pharma and lab partnerships, determine our business development priorities and sharpen our overall execution."

In connection with Mr. van der Mark's appointment as CBO and pursuant 3DS' stock option plan, the Board of Directors of the Company granted Mr. van der Mark 220,000 stock options (the "Options"), exercisable at $0.75, the closing price of the Company's shares on the TSX Venture Exchange on January 5, 2017. The Options will vest in tranches from July 7, 2017 to July 7, 2019 and once vested are exercisable for ten years from the date of grant.

About 3DS

3DS (TSX VENTURE: DXD) (OTCQB: TDSGF) (FRANKFURT: 3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company's website at

Forward-Looking Information

This news release includes forward-looking statements that are subject to assumptions, risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. Forward-looking statements can generally be identified by the use of forwarding looking wording such as "will", "may", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. In particular, the Company's statements, explicit or implied, that it expects to benefit greatly from its association with the individuals named in this news release is forward-looking information. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors and assumptions that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: the ability to obtain all required approvals; the state of the capital markets; market demand; technological changes that could impact the Company's existing products or the Company's ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company's financial condition; the Company's ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in legal, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

For further information, please contact:

Stephen Kilmer
Investor Relations


Hugh Rogers
VP Corporate Finance